TY - JOUR
T1 - Correction of increased prostacyclin synthesis in Bartter's syndrome by indometracin treatment
AU - Gullner, H. G.
AU - Smith, J. B.
AU - Cerletti, C.
AU - Gill, J. R.
AU - Bartter, F. C.
PY - 1980
Y1 - 1980
N2 - The role of prostacyclin and thromboxane A2 in the pathogenesis of Bartter's syndrome was investigated by measurement of the urinary excretion of 6-keto-PGF1α and thromboxane B2, respectively, in five patients. The prostaglandin metaeolites were extracted from urine by a reproducible method and measured by specific radioimmunoassays. The patients with Bartter's syndrome excreted about four-times as much 6-keto-PGF1α as the normal controls.In contrast, there was no significant difference in the urinary excretion of thromboxane B2 between the patients and the controls. In a second part of the study, three patients were treated with indomethacin (150 mg/day for four days), an inhibitor of prostaglandin synthesis. This regimen suppressed urinary excretion of 6-keto-PGF by 437 and that of thromboxane B2 by 467. It is suggested that the increase in prostacyclin production is responsible for both the hyperreninemia and the other endocrine derangements as well as the hyporesponsiveness of blood pressure to intravenous infusion of vasopressors in patients with Bartter's syndrome.
AB - The role of prostacyclin and thromboxane A2 in the pathogenesis of Bartter's syndrome was investigated by measurement of the urinary excretion of 6-keto-PGF1α and thromboxane B2, respectively, in five patients. The prostaglandin metaeolites were extracted from urine by a reproducible method and measured by specific radioimmunoassays. The patients with Bartter's syndrome excreted about four-times as much 6-keto-PGF1α as the normal controls.In contrast, there was no significant difference in the urinary excretion of thromboxane B2 between the patients and the controls. In a second part of the study, three patients were treated with indomethacin (150 mg/day for four days), an inhibitor of prostaglandin synthesis. This regimen suppressed urinary excretion of 6-keto-PGF by 437 and that of thromboxane B2 by 467. It is suggested that the increase in prostacyclin production is responsible for both the hyperreninemia and the other endocrine derangements as well as the hyporesponsiveness of blood pressure to intravenous infusion of vasopressors in patients with Bartter's syndrome.
UR - http://www.scopus.com/inward/record.url?scp=0018916953&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0018916953&partnerID=8YFLogxK
U2 - 10.1016/0161-4630(80)90036-1
DO - 10.1016/0161-4630(80)90036-1
M3 - Article
C2 - 6994153
AN - SCOPUS:0018916953
VL - 4
SP - 65
EP - 72
JO - Prostaglandins and Medicine
JF - Prostaglandins and Medicine
SN - 0161-4630
IS - 2
ER -